Dr
Chibawaye Eneh
A Nigerian Doctor based in the United States, Dr Chibawanye Ene, has won the 2019 Ronald
L. Bittner Award on Brain Tumor Research.
The Clinical Department, Applied Radiation Oncology
U.S. in a release said Ene received the award at the 2019 American Association of
Neurological Surgeons (AANS) Annual Scientific Meeting held from
April 13 to April 17 in San Diego.
Ene
who is from Akpugo in Nkanu West Local Government Area of Enugu
State, won the award with his research work on ‘Anti-PD-L1
Immunotherapy Enhances Radiation-induced Abscopal Response in
Glioblastoma’.
The release which was cited by the News Agency of Nigeria (NAN) reports that Immunotherapy is a type of
cancer treatment that helps immune system fight cancer.
The
immune system, made up of white blood cells, organs and tissues of
the lymph system, helps the body fight infections and other diseases.
The
Clinical Department stated Immunotherapy is a type of biological
therapy.
Also,
Glioblastoma, known as glioblastoma multiforme (GBM), is the most
aggressive cancer that begins within the brain. Initially, signs and
symptoms of glioblastoma are non-specific.
They
may include headaches, personality changes, nausea, and symptoms
similar to those of a stroke.
Immunotherapy
for glioblastoma has been largely unsuccessful in part, because
molecular heterogeneity drives selective elimination of only a subset
of tumor cells.
According
to the statement, it appears that therapeutic success in patients
would require achieving an abscopal effect, where following focused
radiation therapy, non-targeted tumor cells are attacked by the
immune system.
The
statement further revealed that it remains unclear how glioblastoma
respond to focused radiation in terms of failure location and whether
immunotherapy could amplify the immune response to tumor outside the
radiation field.
The
result of the study’s experiment show that radiation combined with
anti PD L1 therapy induces an immunological response to unirradiated
glioblastoma.
The
researchers are currently optimizing other treatment combinations
that could also be readily assessed in phase I human clinical trials.
No comments:
Post a Comment